NEWS HIGHLIGHTSMedia Articles Related to Hydralazine and Hydrochlorothiazide (Hydralazine / Hydrochlorothiazide)
New Consortium Paves The Way For Improved Treatment Of Hypertension And Associated Vascular Complications
Source: Hypertension News From Medical News Today [2009.11.18]
Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
Kids with CKD Often Have Masked Hypertension (CME/CE)
Source: MedPage Today Nephrology [2009.11.13]
Many children with chronic kidney disease may have undetected hypertension, placing them at risk for enlarged hearts and future cardiovascular disease, a cross-sectional study showed.
Key Player Identified In Cascade That Leads To Hypertension-Related Kidney Damage
Source: Hypertension News From Medical News Today [2009.11.06]
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Medical College of Georgia researchers have found endothelin, a powerful blood vessel constrictor and inflammatory peptide, increases the number of T cells in the kidneys, which helps recruit other immune cells, causing inflammation and destruction.
A Recipe For Hypertension: High Fructose Corn Syrup
Source: Hypertension News From Medical News Today [2009.10.31]
A diet high in fructose increases the risk of developing high blood pressure (hypertension), according to a paper presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, California. The findings suggest that cutting back on processed foods and beverages that contain high fructose corn syrup (HFCS) may help prevent hypertension.
Hypertension Guidelines Reappraised In Light Of New Research
Source: Hypertension News From Medical News Today [2009.10.30]
A Task Force of the European Society of Hypertension have released the official European guidelines on the management and treatment of hypertension. The guidelines are an update of those published in 2007, and will be published in the November issue of the Journal of Hypertension.
Published Studies Related to Hydralazine and Hydrochlorothiazide (Hydralazine / Hydrochlorothiazide)
Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report. [1989.04]
A case of retroperitoneal fibrosis possibly associated with hydralazine, hydrochlorothiazide and ampicillin therapy is reported..
Plasma lipid profiles and antihypertensive agents: effects of lisinopril, enalapril, nitrendipine, hydralazine, and hydrochlorothiazide. [1988.07]
Previous studies have documented potentially adverse effects of diuretics and beta-blocking agents on plasma lipid profiles. This study was designed to establish the effects on lipid profiles of the angiotensin-converting enzyme inhibitors lisinopril and enalapril, alone and in combination with hydrochlorothiazide (HCTZ), the calcium-channel blocker nitrendipine, HCTZ, and hydralazine...
Clinical Trials Related to Hydralazine and Hydrochlorothiazide (Hydralazine / Hydrochlorothiazide)
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer [Completed]
The current standard for locally advanced cervical cancer is concurrent cisplatin-based
chemotherapy, however, the treatment results need to be improved. Epigenetic aberrations play
an important role in cancer progression by silencing growth regulatory genes and there is now
evidence that inhibitors of DNA methylation and HDAC inhibition synergize the radiation and
chemotherapy effects.
Objective. To determine response rate, safety and biological effects of hydralazine and
magnesium valproate when added to cisplatin chemoradiation.
Hypothesis. Hydralazine and magnesium valproate associated to chemoradiation will increase
the clinical complete response rate to 95% as compared to 75% as seen in historical controls
treated with cisplatin chemoradiation in FIGO stage IIIB patients.
Metodology. A total of 17 FIGO stage IIIB patients with histologically confirmed cervical
carcinoma with no previous treatment will be included. Patients will be typed for acetylator
status and and then receive either 182 or 83 mg of hydralazine, and magnesium valproate at
40mg/Kg from day - 7 to the end of chemoradiation (external and brachytherapy). Clinical
response rate, safety and transcriptome changes will be analyzed.
Hydralazine and Valproate Added to Chemotherapy for Breast Cancer [Terminated]
Aberrant DNA methylation and histone deacetylation participate in cancer development and
progression, as epigenetic alterations are common to breast cancer, in this phase II study,
the demethylating hydralazine plus the HDAC inhibitor magnesium valproate will be added to
neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess
their safety and biological efficacy.
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors [Completed]
Chemotherapy resistance, either innate or acquired requires for its development, expression
changes on a large number of genes therefore, it has been hypothesized that
epigenetic-mediated changes could be the responsible driving force for chemotherapy
resistance. Aberrant DNA methylation and histone deacetylation are the main epigenetic
alterations hence, their reversal by inhibitors of DNA methylation and histone deacetylases
(HDACs) may overcome resistance in refractory solid tumors.
Patients will be treated with hydralazine and magnesium valproate starting from day - 7 until
chemotherapy ends which consists on the same pre-study protocol regimen on which patients
progressed. Response and toxicity were evaluated. Global DNA methylation and HDAC activity
were evaluated in the peripheral blood cells, as well as the plasma levels of valproic acid
and hydralazine.
Hydralazine Valproate for Ovarian Cancer [Recruiting]
The current standard for recurrent, persistent or metastatic cisplatin-resistant ovarian
cancer is palliative chemotherapy with either topotecan, liposomal doxorubicin or
gemcitabine, however, the results need to be improved. Epigenetic aberrations play an
important role in cancer progression by silencing growth regulatory genes and there is now
evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity
of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate
plus topotecan over placebo plus topotecan upon progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to topotecan will increase
progression-free survival from 6 to 9 months as compared with the same regimen of
chemotherapy plus placebo.
Hydralazine Valproate for Cervical Cancer [Recruiting]
The current standard for recurrent, persistent or metastatic cervical cancer is palliative
chemotherapy with cisplatin topotecan, however, the results need to be improved. Epigenetic
aberrations play an important role in cancer progression by silencing growth regulatory
genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition
synergize the cytotoxicity of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate
plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon
progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to cisplatin topotecan will
increase progression-free survival from 4. 6 to 7. 6 months as compared with the same regimen
of chemotherapy plus placebo.
|
